{"id":171,"date":"2019-10-08T10:29:34","date_gmt":"2019-10-08T14:29:34","guid":{"rendered":"http:\/\/blogs.duanemorris.com\/lifescienceslaw\/?p=171"},"modified":"2019-10-08T10:29:34","modified_gmt":"2019-10-08T14:29:34","slug":"fda-warns-florida-company-cbd-oil-is-not-a-dietary-supplement","status":"publish","type":"post","link":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2019\/10\/08\/fda-warns-florida-company-cbd-oil-is-not-a-dietary-supplement\/","title":{"rendered":"FDA Warns Florida Company: CBD Oil is Not a Dietary Supplement"},"content":{"rendered":"<p>Despite\u00a0<a href=\"https:\/\/blogs.duanemorris.com\/cannabis\/2019\/10\/01\/legislators-urge-fda-to-act-on-hemp-derived-cbd\/\">recent bipartisan calls<\/a>\u00a0on the FDA to regulate hemp-derived CBD products, the U.S. Food &amp; Drug Administration appears to be adhering to the status quo, at least with respect to issuing warning letters to companies deemed noncompliant with existing regulations. Case in point: on September 18, 2019, the FDA\u00a0<a href=\"https:\/\/www.fda.gov\/inspections-compliance-enforcement-and-criminal-investigations\/warning-letters\/alternative-laboratories-586947-09182019\">issued a warning letter<\/a>\u00a0(posted to the FDA\u2019s website last week) to Alternative Laboratories, a dietary supplement manufacturer based in Naples, Florida.<\/p>\n<p>According to the letter, the FDA conducted an inspection of Alternative\u2019s dietary supplement manufacturing facility over five days in May and June; the inspection focused on the adequacy of labels for certain products manufactured and distributed by the company.<\/p>\n<p>To read the full text of this blog post by Duane Morris attorney <a href=\"https:\/\/www.duanemorris.com\/attorneys\/justinmlstern.html\" target=\"_blank\" rel=\"noopener noreferrer\">Justin M. L. Stern<\/a>, please visit the <a href=\"https:\/\/blogs.duanemorris.com\/cannabis\/2019\/10\/08\/fda-warns-florida-company-cbd-oil-is-not-a-dietary-supplement\/\">Duane Morris Cannabis Industry Blog<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Despite\u00a0recent bipartisan calls\u00a0on the FDA to regulate hemp-derived CBD products, the U.S. Food &amp; Drug Administration appears to be adhering to the status quo, at least with respect to issuing warning letters to companies deemed noncompliant with existing regulations. Case in point: on September 18, 2019, the FDA\u00a0issued a warning letter\u00a0(posted to the FDA\u2019s website &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2019\/10\/08\/fda-warns-florida-company-cbd-oil-is-not-a-dietary-supplement\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;FDA Warns Florida Company: CBD Oil is Not a Dietary Supplement&#8221;<\/span><\/a><\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[406,374,360,407,29,388],"ppma_author":[521],"class_list":["post-171","post","type-post","status-publish","format-standard","hentry","category-general","tag-cannabidiol","tag-cannabis","tag-cbd","tag-dietary-supplement","tag-fda","tag-justin-stern"],"authors":[{"term_id":521,"user_id":6,"is_guest":0,"slug":"duanemorris3","display_name":"Duane Morris","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/843ff6e7a8fe5fc92109b47a45f34b6cf0ea499e6e788db23456c838b0ae6747?s=96&d=blank&r=g","author_category":"1","last_name":"Sullivan","first_name":"Margaret","job_title":"","user_url":"http:\/\/www.duanemorris.com","description":"<a href=\"http:\/\/www.duanemorris.com\">Visit the Duane Morris website.<\/a>"}],"_links":{"self":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/171","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/comments?post=171"}],"version-history":[{"count":0,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/171\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/media?parent=171"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/categories?post=171"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/tags?post=171"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/ppma_author?post=171"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}